Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.57 |
| ▸ | YTHDC1 | Q96MU7 | 12/20 | 0.47 |
| ▸ | YTHDF3 | Q7Z739 | 2/20 | 0.37 |
| ▸ | YTHDF1 | Q9BYJ9 | 2/20 | 0.37 |
| ▸ | YTHDF2 | Q9Y5A9 | 2/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8480942 | 0.81 | XDH (0.41) | XDHYTHDC1 | |
| SCHEMBL30677300 | 0.81 | XDH (0.41) | XDHYTHDC1 | |
| SCHEMBL7110908 | 0.81 | XDH (0.41) | XDHADORA3ADORA1 | |
| SCHEMBL12186854 | 0.81 | XDH (0.41) | XDHADORA3ADORA1 | |
| SCHEMBL16366673 | 0.80 | XDH (0.41) | XDHYTHDC1ADORA3ADORA1 | |
| SCHEMBL11876693 | 0.79 | XDH (0.39) | XDHYTHDC1YTHDF2 | |
| SCHEMBL4430662 | 0.79 | XDH (0.39) | XDHYTHDC1YTHDF2 | |
| SCHEMBL12187031 | 0.78 | XDH (0.40) | XDHADORA3ADORA1 | |
| SCHEMBL14196063 | 0.78 | XDH (0.40) | XDH | |
| SCHEMBL19261289 | 0.78 | XDH (0.40) | XDHADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516637-B1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | PLASMIA BIOTECH S L (ES) | 2016-04-20 | — | — | EP | claimed |
| CN-104447746-A | Compound for activating AMPK and application thereof | HUAAN MEDICAL CO LTD | 2015-03-25 | — | — | CN | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| EP-2516637-A1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | Plasmia Biotech, S.L. (ES) | 2012-10-31 | — | — | EP | claimed |
| US-20120264175-A1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | BRILL ENGINES, S.L. (ES) | 2012-10-18 | — | — | US | claimed |
| WO-2011076894-A1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | INSTITUT UNIV. DE CIÈNCIA I TECNOLOGIA, S.A. (ES) | 2011-06-30 | — | — | WO | claimed |
| EP-2338985-A1 | Thermostable biocatalyst combination for nucleoside synthesis | Institut Univ. de Ciència i Tecnologia, s.a. (ES) | 2011-06-29 | — | — | EP | claimed |
| US-20080089957-A1 | Monocotyledon plant indications extract compositions, method of preparation and pharmaceutical compositions containing them | ACADEMIA SINICA (TW) | 2008-04-17 | — | — | US | claimed |
| EP-3778604-B1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA FARBER CANCER INST INC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2025-09-23 | — | — | US | disclosed |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024105159-A1 | LIGANDS OF THE M6A-RNA READERS | UNIVERSITY OF ZURICH (CH) | 2024-05-23 | — | — | WO | disclosed |
| US-20240132533-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-04-25 | — | — | US | disclosed |
| CN-112888696-B | Exonuclease inhibitors and methods of use thereof | 德琪医疗有限公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2008017161-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-02-14 | — | — | WO | disclosed |
| US-5663154-A | VIRICIDES, HIV, HEPATITIS | GLAXO WELLCOME INC. (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0625158-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-23 | — | — | EP | disclosed |
| WO-1993014103-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
| US-5110818-A | Antiepileptic agents | CIBA-GEIGY CORPORATION (US) | 1992-05-05 | — | — | US | disclosed |
| EP-0363320-A2 | Substituted 9H purine | CIBA-GEIGY AG (CH) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132533-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | XDH 337/4885YTHDC1 3612/4885YTHDF3 2812/4885 |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | XDH 253/4885YTHDC1 4697/4885YTHDF3 4649/4885 |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | XDH 337/4885YTHDC1 3612/4885YTHDF3 2812/4885 |
| US-20080089957-A1 | Monocotyledon plant indications extract compositions, method of preparation and pharmaceutical compositions containing them | OAT, TPMT, NUDT1 | XDH 5/4885YTHDC1 783/4885YTHDF3 619/4885 |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | XDH 2699/4885YTHDC1 3450/4885YTHDF3 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.